335 related articles for article (PubMed ID: 28813502)
1. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.
Gronde TV; Uyl-de Groot CA; Pieters T
PLoS One; 2017; 12(8):e0182613. PubMed ID: 28813502
[TBL] [Abstract][Full Text] [Related]
2. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
4. Do market components account for higher US prescription prices?
Monaghan MJ; Monaghan MS
Ann Pharmacother; 1996 Dec; 30(12):1489-94. PubMed ID: 8968463
[TBL] [Abstract][Full Text] [Related]
5. Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon.
Abdel Rida N; Mohamed Ibrahim MI; Babar ZUD
BMC Health Serv Res; 2019 Dec; 19(1):973. PubMed ID: 31852546
[TBL] [Abstract][Full Text] [Related]
6. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
Morgan SG; Li W; Yau B; Persaud N
CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
[TBL] [Abstract][Full Text] [Related]
7. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
[TBL] [Abstract][Full Text] [Related]
8. Pricing and availability of some essential child specific medicines in Odisha.
Swain TR; Rath B; Dehury S; Tarai A; Das P; Samal R; Samal S; Nayak H
Indian J Pharmacol; 2015; 47(5):496-501. PubMed ID: 26600637
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
[TBL] [Abstract][Full Text] [Related]
10. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
Bendicksen L; Rome BN; Avorn J; Kesselheim AS
Milbank Q; 2021 Dec; 99(4):1162-1197. PubMed ID: 34375015
[TBL] [Abstract][Full Text] [Related]
11. An economic justification for open access to essential medicine patents in developing countries.
Flynn S; Hollis A; Palmedo M
J Law Med Ethics; 2009; 37(2):184-208. PubMed ID: 19493066
[TBL] [Abstract][Full Text] [Related]
12. Reducing Branded Prescription Drug Prices: A Review of Policy Options.
Alexander GC; Ballreich J; Socal MP; Karmarkar T; Trujillo A; Greene J; Sharfstein J; Anderson G
Pharmacotherapy; 2017 Nov; 37(11):1469-1478. PubMed ID: 28805961
[TBL] [Abstract][Full Text] [Related]
13. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
Danzon PM; Towse A
Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
[TBL] [Abstract][Full Text] [Related]
14. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
[TBL] [Abstract][Full Text] [Related]
15. Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases.
Ewen M; Zweekhorst M; Regeer B; Laing R
PLoS One; 2017; 12(2):e0171284. PubMed ID: 28170413
[TBL] [Abstract][Full Text] [Related]
16. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.
Moodley R; Suleman F
BMC Health Serv Res; 2019 Aug; 19(1):576. PubMed ID: 31419977
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.
Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU
PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276
[TBL] [Abstract][Full Text] [Related]
19. The impacts and unintended consequences of the nationwide pricing reform for drugs and medical services in the urban public hospitals in China.
Zhang X; Lai H; Zhang L; He J; Fu B; Jin C
BMC Health Serv Res; 2020 Nov; 20(1):1058. PubMed ID: 33225941
[TBL] [Abstract][Full Text] [Related]
20. Killing U.S. Slowly: Curing the Epidemic Rise of Cancer Drug Prices.
White EK
Food Drug Law J; 2017; 72(1):189-224. PubMed ID: 29140658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
